High-Flow Nasal Cannula (HFNC): An Advanced Respiratory Support System

Abstract

High-Flow Nasal Cannula (HFNC) therapy has revolutionized oxygen delivery by providing heated, humidified oxygen at high flow rates, offering significant advantages over conventional oxygen therapy (COT) and non-invasive ventilation (NIV). Originally developed for neonates, HFNC is now widely used in adult respiratory care, particularly in managing acute respiratory failure and post-COVID-19 complications. It improves oxygenation, reduces work of breathing, and enhances patient comfort. Despite its higher cost and some limitations, HFNC has proven to be an effective and well-tolerated modality in various clinical scenarios, with ongoing research exploring its full potential.